RevImmune advances new immunotherapy in COVID-19
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
BETHESDA, Maryland, Nov. 3, 2020 /PRNewswire-AsiaNet/ -- RevImmune, a privately held biotech company based in Paris, France and Bethesda, MD, developing CYT107 (recombinant human Interleukin-7) for infectious diseases, sepsis and cancer, announced today that its "ILIAD-7" international randomized contro...
Authors: LATEST ASIANET NEWS RELEASES